{"id":"doi:10.1016/j.neurot.2025.e00570","kind":"review","title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions","authors":["Jeffrey L. Cummings"],"author_count":1,"year":2025,"published":"2025-03-20","venue":"Neurotherapeutics","cited_by":79,"doi":"10.1016/j.neurot.2025.e00570","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.neurot.2025.e00570","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.neurot.2025.e00570","updated":null,"pmid":"40118715","pmcid":null,"openalex_id":"W4408656563","pdf_url":null,"abstract":null,"abstract_license":null,"license":"cc-by-nc-nd","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer's disease research and treatments"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}